Dermapharm Holding SE Statistics

Total Valuation

LON:0A5J has a market cap or net worth of GBP 1.74 billion. The enterprise value is 2.49 billion.

Market Cap	1.74B
Enterprise Value	2.49B

Important Dates

The next estimated earnings date is Thursday, May 15, 2025.

Earnings Date	May 15, 2025
Ex-Dividend Date	Jun 27, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.72%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	14.14M

Valuation Ratios

The trailing PE ratio is 18.49.

PE Ratio	18.49
Forward PE	n/a
PS Ratio	1.76
PB Ratio	3.46
P/TBV Ratio	n/a
P/FCF Ratio	12.89
P/OCF Ratio	10.44
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.24, with an EV/FCF ratio of 18.43.

EV / Earnings	26.42
EV / Sales	2.43
EV / EBITDA	11.24
EV / EBIT	12.99
EV / FCF	18.43

Financial Position

The company has a current ratio of 1.82, with a Debt / Equity ratio of 1.63.

Current Ratio	1.82
Quick Ratio	0.72
Debt / Equity	1.63
Debt / EBITDA	3.85
Debt / FCF	6.07
Interest Coverage	3.80

Financial Efficiency

Return on equity (ROE) is 19.38% and return on invested capital (ROIC) is 8.58%.

Return on Equity (ROE)	19.38%
Return on Assets (ROA)	6.55%
Return on Invested Capital (ROIC)	8.58%
Return on Capital Employed (ROCE)	12.67%
Revenue Per Employee	273,852
Profits Per Employee	26,066
Employee Count	3,610
Asset Turnover	0.56
Inventory Turnover	1.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +17.18% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+17.18%
50-Day Moving Average	38.41
200-Day Moving Average	36.29
Relative Strength Index (RSI)	52.76
Average Volume (20 Days)	22,496

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LON:0A5J had revenue of GBP 988.61 million and earned 94.10 million in profits. Earnings per share was 1.75.

Revenue	988.61M
Gross Profit	620.11M
Operating Income	183.65M
Pretax Income	142.24M
Net Income	94.10M
EBITDA	207.38M
EBIT	183.65M
Earnings Per Share (EPS)	1.75

Full Income Statement

Balance Sheet

The company has 100.80 million in cash and 818.91 million in debt, giving a net cash position of -718.11 million.

Cash & Cash Equivalents	100.80M
Total Debt	818.91M
Net Cash	-718.11M
Net Cash Per Share	n/a
Equity (Book Value)	503.04M
Book Value Per Share	9.28
Working Capital	220.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 166.53 million and capital expenditures -31.62 million, giving a free cash flow of 134.91 million.

Operating Cash Flow	166.53M
Capital Expenditures	-31.62M
Free Cash Flow	134.91M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 62.73%, with operating and profit margins of 18.58% and 9.52%.

Gross Margin	62.73%
Operating Margin	18.58%
Pretax Margin	14.39%
Profit Margin	9.52%
EBITDA Margin	20.98%
EBIT Margin	18.58%
FCF Margin	13.65%

Dividends & Yields

This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.96%.

Dividend Per Share	0.75
Dividend Yield	1.96%
Dividend Growth (YoY)	-17.00%
Years of Dividend Growth	n/a
Payout Ratio	41.64%
Buyback Yield	n/a
Shareholder Yield	1.96%
Earnings Yield	5.41%
FCF Yield	7.76%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0A5J has an Altman Z-Score of 2.15. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.15
Piotroski F-Score	n/a